SEC Company Response from Entrada Therapeutics, (TRDA) — Dec 1, 2025
Entrada Therapeutics, Inc.
Date: Dec. 1, 2025 · CIK: 0001689375 · Accession: 0001104659-25-117409
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-291306
Letter
VIA EDGAR
December 1, 2025
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Daniel Crawford
Re: Entrada Therapeutics, Inc.
Acceleration Request for Registration Statement on Form S-3
Filed November 6, 2025
File No. 333-291306
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the " Act "), Entrada Therapeutics, Inc. (the " Company ") hereby requests that the effective date of the above- referenced registration statement (the " Registration Statement ") be accelerated to December 3, 2025, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our outside counsel, Goodwin Procter LLP, by calling Sarah Ashfaq at (212) 459-7238. If you have any questions regarding this request, please contact Sarah Ashfaq of Goodwin Procter LLP at (212) 459-7238.
Sincerely,
Entrada Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm VIA EDGAR December 1, 2025 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Daniel Crawford Re: Entrada Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 Filed November 6, 2025 File No. 333-291306 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the " Act "), Entrada Therapeutics, Inc. (the " Company ") hereby requests that the effective date of the above- referenced registration statement (the " Registration Statement ") be accelerated to December 3, 2025, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our outside counsel, Goodwin Procter LLP, by calling Sarah Ashfaq at (212) 459-7238. If you have any questions regarding this request, please contact Sarah Ashfaq of Goodwin Procter LLP at (212) 459-7238. Sincerely, Entrada Therapeutics, Inc. /s/ Kory Wentworth Kory Wentworth Chief Financial Officer cc: Dipal Doshi, Entrada Therapeutics, Inc. Jared Cohen, Entrada Therapeutics, Inc. Kingsley L. Taft, Esq., Goodwin Procter LLP Sarah Ashfaq, Esq., Goodwin Procter LLP